Esperion Therapeutics, Inc.
(NASDAQ : ESPR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading ESPR News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.18%165.741.2%$778.89m
INCYIncyte Corporation
0.48%139.641.7%$592.23m
GILDGilead Sciences, Inc.
0.03%67.511.0%$577.68m
CELGCelgene Corporation
0.13%123.381.0%$494.27m
BIIBBiogen Inc.
-0.21%274.821.3%$452.48m
REGNRegeneron Pharmaceuticals, Inc.
2.19%373.002.1%$320.06m
KITEKite Pharma, Inc.
3.14%76.8418.8%$224.79m
ALXNAlexion Pharmaceuticals, Inc.
-0.83%119.261.6%$202.56m
TSROTESARO, Inc.
4.15%160.0016.1%$189.31m
ESPREsperion Therapeutics, Inc.
-3.61%38.9418.7%$173.60m
ILMNIllumina, Inc.
1.72%170.583.7%$172.89m
AUPHAurinia Pharmaceuticals Inc.
-4.41%8.026.3%$150.20m
CLVSClovis Oncology, Inc.
2.61%70.3217.5%$142.57m
VRTXVertex Pharmaceuticals Incorporated
1.04%89.982.2%$135.11m
EXELExelixis, Inc.
2.95%20.917.0%$105.88m

Company Profile

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company focuses on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. It is in business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The company was founded by Roger S. Newton and Charles L. Bisgaier on January 22, 2008 and is headquartered in Ann Arbor, MI.